Related Experiment Video
Updated: Jul 21, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
CYP2D6 polymorphism in a Mexican American population.
R Mendoza1, Y J Wan, R E Poland
1Department of Psychiatry, UCLA School of Medicine, Harbor-UCLA Medical Center, Torrance, CA 90502, USA.
Clinical Pharmacology and Therapeutics
|December 26, 2001
Summary
Mexican Americans show a lower frequency of the CYP2D6*4 allele compared to Caucasians. This genetic pattern may influence drug metabolism rates in this population.
Area of Science:
- Pharmacogenomics
- Genetics
- Population Studies
Background:
- Limited pharmacogenetic data exists for Mexican Americans, a significant demographic group.
- Understanding genetic variations in drug metabolism is crucial for personalized medicine.
Purpose of the Study:
- To investigate the CYP2D6 genotype and dextromethorphan hydroxylation phenotype in Mexican Americans.
- To establish baseline pharmacogenetic data for this underrepresented population.
Main Methods:
- Genotyping for CYP2D6 alleles in 349 Mexican American subjects.
- Phenotyping using dextromethorphan hydroxylation in 285 subjects.
- Analysis of allelic frequencies and metabolizer status.
Main Results:
- Identified specific allelic frequencies for CYP2D6 variants (e.g., CYP2D6*2, CYP2D6*4).
- Observed a 3.2% incidence of poor metabolizers, lower than in some Caucasian populations.
- Correlated the number of functional alleles with metabolic phenotype, indicating a gene-dose effect.
Conclusions:
- Mexican Americans exhibit a lower frequency of the CYP2D6*4 allele compared to Caucasians.
- Observed genotypic patterns may explain differences in poor metabolizer rates and enzyme activity.
- This study provides essential pharmacogenetic insights for the Mexican American population.
Related Concept Videos
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...